A2 Vertaisarvioitu katsausartikkeli tieteellisessä lehdessä

Contraindications to immunotherapy: a global approach




TekijätPitsios C, Tsoumani M, Bilo MB, Sturm GJ, del Rio PR, Gawlik R, Rueff F, Paraskevopoulos G, Valovirta E, Pfaar O, Calderon MA, Demoly P

KustantajaBMC

Julkaisuvuosi2019

JournalClinical and Translational Allergy

Tietokannassa oleva lehden nimiCLINICAL AND TRANSLATIONAL ALLERGY

Lehden akronyymiCLIN TRANSL ALLERGY

Artikkelin numeroARTN 45

Vuosikerta9

Numero1

Sivujen määrä10

eISSN2045-7022

DOIhttps://doi.org/10.1186/s13601-019-0285-4

Rinnakkaistallenteen osoitehttps://research.utu.fi/converis/portal/detail/Publication/42571278


Tiivistelmä
Background Recommendations on contraindications to allergen immunotherapy (AIT) have been independently developed by National and International Societies/Academies. AIT contraindications are mainly based on case reports, case-series, or experts' opinion, while evidence-based information is limited. The aim of the present review was to describe existing guidelines on contraindications to AIT and to highlight differences between them. Main body An extended review of the literature regarding contraindications to AIT for respiratory allergy and venom hypersensitivity was performed. Furthermore, Societies and Academies registered in the World Allergy Organization and EAACI databases, were asked for additional information. Only AIT guidelines published under official auspicies were included. A large heterogeneity among the various recommendations on contraindications was registered. Common contraindications to most of the guidelines were: lack of adherence, pregnancy before the start of AIT, the use of beta-blockers, certain age groups, uncontrolled asthma, autoimmune diseases and malignancies. Conclusion As new data arise, revisions might soon be needed allowing AIT in the cases of patients treated with ACE inhibitors and beta-blockers, in elderly patients and in patients with concomitant autoimmune diseases and neoplasias in remission. The decision to prescribe AIT is always tailor-made, balancing risk vs benefit. Creating globally accepted guidelines would help Allergologists in their decision making.

Ladattava julkaisu

This is an electronic reprint of the original article.
This reprint may differ from the original in pagination and typographic detail. Please cite the original version.





Last updated on 2024-26-11 at 14:37